Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

REVENUE (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended							1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013 Collaboration arrangement for development and commercialization of oral rotavirus strain Glaxo Rotarix	Dec. 31, 2012 Collaboration arrangement for development and commercialization of oral rotavirus strain Glaxo Rotarix	Dec. 31, 2011 Collaboration arrangement for development and commercialization of oral rotavirus strain Glaxo Rotarix	Dec. 31, 1995 License agreements Cincinnati Children's Hospital Medical Center Rotarix	May 31, 2005 Royalty Agreement PRF Rotarix
REVENUE
Percentage of license fee payable on net royalties received							30.00%
Percentage of interest in net royalties sold								70.00%
Product royalty expense	$ 2,334	$ 10,775	$ 9,119	$ 2,300	$ 10,800	$ 9,100